Today's research leads to
a healthier tomorrow

New solutions for
keeping watch over
man's best friend.

An innovative approach for
early canine cancer detection.

The Right Test for
the Right Diagnosis

Our compassion for our pets is at the heart of our innovation.

We are pioneers, innovators and researchers – and we are also dog lovers. That’s why we are driven to understand the biological and environmental influences of canine cancer, to create solutions for accurate and early detection that will help to enhance the health and welfare of our canine companions.

“Having a non-invasive urine analysis test gives us a quick, definitive diagnosis for TCC/UC when pricey advanced diagnostics (ultrasound/cystoscopy) may not be feasible, giving us more time and resources for treatment.”

Theresa Arteaga, DVM, DACVIM (Oncology)
Animal Cancer Center, Monterey, CA

Theresa Arteaga

“The CADET BRAF assay offers trusted results, with high sensitivity and specificity levels to support diagnosis and monitor effectiveness of treatment for TCC/UC.”

Lindsay Thalheim, DVM, DACVIM (Oncology)
Staff Oncologist Specialist & Adjunct Assistant Clinical Professor of Oncology, Cornell University College of Veterinary Medicine

Lindsay Thalheim

“With the CADET BRAF test, clinicians can test the efficacy of treatment quickly, precisely, and non-invasively.”

Jerold Bell, DVM
Freshwater Veterinary Hospital, Enfield, CT

Jerold Bell

“Earlier and less invasive bladder cancer detection allows earlier intervention to improve quality of life and extend survival. When older dogs from high-risk breeds present with non-specific urinary symptoms, we immediately screen for TCC/UC with the CADET BRAF assay, for a fast and reliable result.”

Betsy Sigmon, DVM
Creature Comforts Animal Hospital, Cary, NC

Betsy Sigmon

“The CADET BRAF assay provides an objective way to document TCC/UC for initial diagnosis and then monitoring. Other diagnostic tools like ultrasounds can be subjective and inconclusive, and cannot detect small changes in tumor burden during TCC/UC treatment. The CADET BRAF assay allows us to progressively monitor BRAF-positive tumors for response to treatment.”

Gerald Post, DVM, MEM, DACVIM (Oncology)
Chief Medical Officer, The Veterinary Cancer Center, Norwalk, CT

Gerald Post

“The CADET BRAF assay has the potential to be a game-changer for how we diagnose TCC/UC and how we treat and manage the disease once detected. This will pick up the disease earlier, before clinical signs appear, giving us more treatment options and giving owners an opportunity to spend their money treating the disease rather than on expensive diagnostics.”

Shelly Vaden, DVM, PhD, DACVIM
Professor of Internal Medicine,
North Carolina State University College of Veterinary Medicine
President of the American Society
 of Veterinary Nephrology and Urology

Shelly Vaden

Learn more about our CADET SM solutions for canine CAncer DETection



A range of products designed for early detection, diagnosis and monitoring of canine bladder cancer – also known as transitional cell carcinoma (TCC)/urothelial carcinoma (UC)

For more information, please select one of the following options:



A powerful new approach for distinction between canine histiocytic malignancy (HM) and other round cell tumors, including lymphoma and hemangiosarcoma

For more information, please select one of the following options: